Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

American Heart Association meeting

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

Havas Lynx Group scoops nine Golds at PM Society Awards

Sanofi Genzyme and Regeneron topped the pharma company charts

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

- PMLiVE

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

- PMLiVE

Regeneron’s early stage bispecific shows promise

Bispecifics and antibody drug conjugates will challenge CAR-Ts

- PMLiVE

CHMP backs Sanofi’s all-oral sleeping sickness drug

Sanofi's drug and others given green light by EMA committee

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links